Use of an antibody against the laminin receptor or laminin...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01) A61P 35/04 (2006.01) C07K 16/46 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2603480

Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment of various cancers. Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.

Utilisation d'anticorps contre le récepteur de laminine ou son précurseur pour le traitement de différents cancers. On décrit l'utilisation d'un anticorps de recombinaison qui comprend un site de liaison spécifique à l'épitope du récepteur considéré ou de son précurseur, pour le traitement ou le diagnostic de différents cancers, en particulier B-CLL. De préférence, cet anticorps comprend aussi un site de liaison pour au moins un antigène de surface cellulaire particulier.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of an antibody against the laminin receptor or laminin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of an antibody against the laminin receptor or laminin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an antibody against the laminin receptor or laminin... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1967246

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.